Literature DB >> 33916652

Renal Cell Carcinoma with or without Tumor Thrombus Invading the Liver, Pancreas and Duodenum.

Javier González1, Jeffrey J Gaynor2, Gaetano Ciancio2,3.   

Abstract

BACKGROUND: The purpose of this study is to report the outcomes of a series of patients with locally advanced renal cell carcinoma (RCC) who underwent radical nephrectomy, tumor thrombectomy, and visceral resection. PATIENTS AND METHODS: 18 consecutive patients who underwent surgical treatment in the period 2003-2019 were included. Neoplastic extension was found extending into the pancreas, duodenum, and liver in 9(50%), 2(11.1%), and 7(38.8%) patients, respectively. Seven patients (38.8%) presented also inferior vena cava tumor thrombus level I (n = 3), II (n = 2), or III (n = 2). The resection was tailored according to the degree of invasiveness. Demographics, clinical presentation, disease characteristics, surgical details, 30-day postoperative complications, and overall survival (OS) were analyzed.
RESULTS: Median age was 56 years (range: 40-76). Median tumor size was 14.5 cm (range, 8.8-22), and 10 cm (range: 4-15) for those cases with pancreatico-duodenal and liver involvement, respectively. Median estimated blood loss (EBL) was 475 mL (range: 100-4000) and resulted higher for those cases requiring thrombectomy (300 mL vs. 750 mL). Nine patients (50%) required transfusions with a median requirement of 4 units (range: 2-8). No perioperative deaths were registered in the first 30 days. Overall complication rate was 44.4%. Major complications were detected in 6/18 patients (33.3%). Overall median follow-up was 24 months (range: 0-108). Five-year OS (actuarial) rate was 89.9% and 75%, for 9/11 patients with pancreatico-duodenal involvement and 6/7 patients with liver invasion, respectively.
CONCLUSION: Our series establishes the technical feasibility of this procedure with acceptable complication rates, no deaths, and potential for durable response.

Entities:  

Keywords:  metastasectomy; oncological outcomes; postoperative complications; renal cell carcinoma; tumor thrombus

Year:  2021        PMID: 33916652     DOI: 10.3390/cancers13071695

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  2 in total

1.  Urological Cancer Panorama in the Second Year of the COVID-19 Pandemic.

Authors:  Estibaliz López-Fernández; Javier C Angulo; José I López; Claudia Manini
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

2.  Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas.

Authors:  Mohamed Sharafeldeen; Vahid Mehrnoush; Asmaa Ismail; Ahmed Zakaria; Hazem Elmansy; Walid Shahrour; Owen Prowse; Ahmed Kotb
Journal:  J Kidney Cancer VHL       Date:  2022-08-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.